On 11 September 2026, the Dubai Health Authority (DHA), through its Drug Control & Inspection Section, conducted a workshop on Regulations for Handling Peptide Products in Healthcare Facilities, following Circular CIR-2026-00000107 issued on 29 July 2026.
What healthcare facilities should review
- The regulatory status of peptide products used or supplied within the facility.
- The legitimacy and authorization of supply sources.
- Procurement records and supporting documentation.
- Storage and handling controls appropriate to each product.
- Traceability and internal procedures against applicable UAE requirements.
Implications for manufacturers and international companies
Regulatory planning should begin before peptide products are supplied to healthcare facilities in the UAE. Product classification, registration requirements, local representation, supply-chain arrangements and post-market responsibilities should be assessed as part of the market-entry strategy.
ViaFarma Solutions supports pharmaceutical and healthcare companies with UAE regulatory assessment, product registration, market-entry planning and regulatory compliance support.
